Edgewise Therapeutics' EDG-7500 Seen Entering 'Catalyst-Dense' Regulatory Period, Oppenheimer Says

Like
Comment
Favorite

Edgewise Therapeutics' EDG-7500 Seen Entering 'Catalyst-Dense' Regulatory Period, Oppenheimer Says

MT Newswires Live07-09 23:17

Edgewise Therapeutics (EWTX) is entering a "catalyst-dense" period for EDG-7500, highlighted by an end-of-phase 2 FDA meeting in H2 and the planned start of a phase 3 study in Q4, Oppenheimer said in a Thursday note.

The company delivered a de-risking phase 2 readout, indicating that EDG-7500 has the potential to ease obstruction without weakening the heart muscle and could corner a share of the growing HCM market if approved.

In addition, Edgewise's $1.55 billion sale of Sevasemten and its muscular dystrophy portfolio in June is expected to keep the company fully funded for the planned phase 3 studies and through product commercialization, Oppenheimer said.

Oppenheimer initiated coverage of Edgewise Therapeutics with an outperform rating and a $51 price target.

Shares of Edgewise were up 2.7% in Thursday trading.

Price: 47.56, Change: +1.26, Percent Change: +2.72

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2650973396?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 23:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650973396","market":"sh","top_or_hot":-1,"title":"Edgewise Therapeutics' EDG-7500 Seen Entering 'Catalyst-Dense' Regulatory Period, Oppenheimer Says","media":"MT Newswires Live","content":"<html><body><p> Edgewise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (EWTX) is entering a \"catalyst-dense\" period for EDG-7500, highlighted by an end-of-phase 2 FDA meeting in H2 and the planned start of a phase 3 study in Q4, Oppenheimer said in a Thursday note.</p><p>The company delivered a de-risking phase 2 readout, indicating that EDG-7500 has the potential to ease obstruction without weakening the heart muscle and could corner a share of the growing HCM market if approved.</p><p>In addition, Edgewise's $1.55 billion sale of Sevasemten and its muscular dystrophy portfolio in June is expected to keep the company fully funded for the planned phase 3 studies and through product commercialization, Oppenheimer said.</p><p>Oppenheimer initiated coverage of Edgewise Therapeutics with an outperform rating and a $51 price target.</p><p>Shares of Edgewise were up 2.7% in Thursday trading.</p><p>Price: 47.56, Change: +1.26, Percent Change: +2.72</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Edgewise Therapeutics' EDG-7500 Seen Entering 'Catalyst-Dense' Regulatory Period, Oppenheimer Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEdgewise Therapeutics' EDG-7500 Seen Entering 'Catalyst-Dense' Regulatory Period, Oppenheimer Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-09 23:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Edgewise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (EWTX) is entering a \"catalyst-dense\" period for EDG-7500, highlighted by an end-of-phase 2 FDA meeting in H2 and the planned start of a phase 3 study in Q4, Oppenheimer said in a Thursday note.</p><p>The company delivered a de-risking phase 2 readout, indicating that EDG-7500 has the potential to ease obstruction without weakening the heart muscle and could corner a share of the growing HCM market if approved.</p><p>In addition, Edgewise's $1.55 billion sale of Sevasemten and its muscular dystrophy portfolio in June is expected to keep the company fully funded for the planned phase 3 studies and through product commercialization, Oppenheimer said.</p><p>Oppenheimer initiated coverage of Edgewise Therapeutics with an outperform rating and a $51 price target.</p><p>Shares of Edgewise were up 2.7% in Thursday trading.</p><p>Price: 47.56, Change: +1.26, Percent Change: +2.72</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2650973396","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2650973396","pubTimestamp":1783610221,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Edgewise Therapeutics  is entering a \"catalyst-dense\" period for EDG-7500, highlighted by an end-of-phase 2 FDA meeting in H2 and the planned start of a phase 3 study in Q4, Oppenheimer said in a Thursday note.The company delivered a de-risking phase 2 readout, indicating that EDG-7500 has the potential to ease obstruction without weakening the heart muscle and could corner a share of the growing HCM market if approved.In addition, Edgewise's $1.55 billion sale of Sevasemten and its muscular dystrophy portfolio in June is expected to keep the company fully funded for the planned phase 3 studies and through product commercialization, Oppenheimer said.Oppenheimer initiated coverage of Edgewise Therapeutics with an outperform rating and a $51 price target.Shares of Edgewise were up 2.7% in Thursday trading.Price: 47.56, Change: +1.26, Percent Change: +2.72","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","OPY":"奥本海默控股","BK4127":"投资银行业与经纪业","EWTX":"Edgewise Therapeutics, Inc.","BK4007":"制药"},"translate_title":"奥本海默表示，Edgewise Therapeutics 的 EDG-7500 进入“催化剂密集”监管期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWTX":1.5,"OPY":1.5},"content_text":"Edgewise Therapeutics (EWTX) is entering a \"catalyst-dense\" period for EDG-7500, highlighted by an end-of-phase 2 FDA meeting in H2 and the planned start of a phase 3 study in Q4, Oppenheimer said in a Thursday note.The company delivered a de-risking phase 2 readout, indicating that EDG-7500 has the potential to ease obstruction without weakening the heart muscle and could corner a share of the growing HCM market if approved.In addition, Edgewise's $1.55 billion sale of Sevasemten and its muscular dystrophy portfolio in June is expected to keep the company fully funded for the planned phase 3 studies and through product commercialization, Oppenheimer said.Oppenheimer initiated coverage of Edgewise Therapeutics with an outperform rating and a $51 price target.Shares of Edgewise were up 2.7% in Thursday trading.Price: 47.56, Change: +1.26, Percent Change: +2.72","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}